{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:10:31Z","timestamp":1772539831945,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03344-y","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T09:53:45Z","timestamp":1756893225000},"page":"5515-5528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Retrospective Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Zi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"3344_CR1","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679\u2013705.","journal-title":"Am J Hematol"},{"key":"3344_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","volume":"404","author":"N Jain","year":"2024","unstructured":"Jain N, Wierda WG, O\u2019Brien S. Chronic lymphocytic leukaemia. Lancet (London, England). 2024;404:694\u2013706.","journal-title":"Lancet (London, England)"},{"key":"3344_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022;21:4.","journal-title":"Biomed Eng Online"},{"key":"3344_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s11864-023-01112-0","volume":"24","author":"P Islam","year":"2023","unstructured":"Islam P. Current treatment options in relapsed and refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: a review. Curr Treat Options Oncol. 2023;24:1259\u201373.","journal-title":"Curr Treat Options Oncol"},{"key":"3344_CR5","unstructured":"Wierda WG, Brown J, Abramson JS, et al. Chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2025."},{"key":"3344_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hon.2695","volume":"38","author":"S Molica","year":"2020","unstructured":"Molica S, Matutes E, Tam C, Polliack A. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematol Oncol. 2020;38:129\u201336.","journal-title":"Hematol Oncol"},{"key":"3344_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138\u201340.","journal-title":"Blood"},{"key":"3344_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919\u201328.","journal-title":"Blood"},{"key":"3344_CR9","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"J-E Salem","year":"2019","unstructured":"Salem J-E, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"3344_CR10","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"3344_CR11","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al., editors. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Proceedings of the 2021 European hematology association virtual congress. 2021."},{"key":"3344_CR12","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after Venetoclax-Obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049\u201360.","journal-title":"J Clin Oncol"},{"key":"3344_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:1423\u201333.","journal-title":"Lancet Oncol"},{"key":"3344_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"DS Orelabrutinib","year":"2021","unstructured":"Orelabrutinib DS. First approval. Drugs. 2021;81:503\u20137.","journal-title":"Drugs"},{"key":"3344_CR15","doi-asserted-by":"publisher","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2020-CT132","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhao R, Liang R, et al. Abstract CT132: Orelabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties. Cancer Res. 2020;80:CT132.","journal-title":"Cancer Res."},{"key":"3344_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.26826","volume":"98","author":"W Xu","year":"2023","unstructured":"Xu W, Zhou K, Wang T, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 2023;98:571\u20139.","journal-title":"Am J Hematol"},{"key":"3344_CR17","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1182\/blood-2021-146491","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu W, Song Y, Wang T, et al. Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: updated long term results of phase II study. Blood. 2021;138:2638.","journal-title":"Blood"},{"key":"3344_CR18","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1182\/blood-2024-204881","volume":"144","author":"H Zhu","year":"2024","unstructured":"Zhu H, Miao Y, Qin S, et al. Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated study (cwCLL-001 study). Blood. 2024;144:3244.","journal-title":"Blood"},{"key":"3344_CR19","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1080\/14656566.2022.2144218","volume":"23","author":"D Gu","year":"2022","unstructured":"Gu D, Li J, Miao Y. Evaluating orelabrutinib as a novel treatment option for relapsed\/refractory chronic lymphocytic leukemia in China. Expert Opin Pharmacother. 2022;23:1979\u201386.","journal-title":"Expert Opin Pharmacother"},{"key":"3344_CR20","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. IWCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"3344_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787\u201398.","journal-title":"Leukemia"},{"key":"3344_CR22","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"3344_CR23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910\u20139.","journal-title":"Blood"},{"key":"3344_CR24","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1182\/blood.2020009617","volume":"137","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021;137:3327\u201338.","journal-title":"Blood"},{"key":"3344_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England). 2020;395:1278\u201391.","journal-title":"Lancet (London, England)"},{"key":"3344_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2019-128404","volume":"134","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019;134:31.","journal-title":"Blood"},{"key":"3344_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-134280","volume":"136","author":"JR Brown","year":"2020","unstructured":"Brown JR, Robak T, Ghia P, et al. Efficacy and safety of zanubrutinib in patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del (17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial. Blood. 2020;136:11\u20132.","journal-title":"Blood"},{"key":"3344_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031\u201343.","journal-title":"Lancet Oncol"},{"key":"3344_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"3344_CR30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035\u201345.","journal-title":"J Clin Oncol"},{"key":"3344_CR31","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849\u201361.","journal-title":"J Clin Oncol"},{"key":"3344_CR32","first-page":"701","volume":"104","author":"S Yang","year":"2025","unstructured":"Yang S, Huang H, Zhou K, et al. Acalabrutinib in Chinese patients with relapsed\/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1\/2 trial. Ann Hematol. 2025;104:701\u201312.","journal-title":"Ann Hematol"},{"key":"3344_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hon.55_2629","volume":"37","author":"W Xu","year":"2019","unstructured":"Xu W, Yang S, Zhou K, et al. Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia. Hematol Oncol. 2019;37:87\u20138.","journal-title":"Hematol Oncol"},{"key":"3344_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918\u201332.","journal-title":"JAMA"},{"key":"3344_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/hematolrep16020027","volume":"16","author":"S Mouhssine","year":"2024","unstructured":"Mouhssine S, Maher N, Kogila S, Cerchione C, Martinelli G, Gaidano G. Current therapeutic sequencing in chronic lymphocytic leukemia. Hematol Rep. 2024;16:270\u201382.","journal-title":"Hematol Rep"},{"key":"3344_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65\u201375.","journal-title":"Lancet Oncol"},{"key":"3344_CR37","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","volume":"98","author":"L Deng","year":"2023","unstructured":"Deng L, Li Z, Zhang H, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: a phase 2, multicenter, open-label study. Am J Hematol. 2023;98:1742\u201350.","journal-title":"Am J Hematol"},{"key":"3344_CR38","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","volume":"40","author":"J-J Wu","year":"2022","unstructured":"Wu J-J, Wang W-H, Dong M, et al. Orelabrutinib-Bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs. 2022;40:650\u20139.","journal-title":"Invest New Drugs"},{"key":"3344_CR39","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581\u20134.","journal-title":"Blood"},{"key":"3344_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.amjcard.2015.05.045","volume":"116","author":"MP Turakhia","year":"2015","unstructured":"Turakhia MP, Shafrin J, Bognar K, et al. Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States. Am J Cardiol. 2015;116:733\u20139.","journal-title":"Am J Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03344-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:29Z","timestamp":1762030949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03344-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3344"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03344-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zi Wang, Congwei Jia, Xuan Wang, Yan Zhang, Daobin Zhou, Wei Zhang have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (Approval Number: I-24PJ0086). The requirement for informed patient consent was waived by the ethical review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}